Sagent Pharmaceuticals Company Profile (NASDAQ:SGNT)

About Sagent Pharmaceuticals

Sagent Pharmaceuticals logoSagent Pharmaceuticals, Inc. is a specialty and generic pharmaceutical company. The Company is a provider of pharmaceuticals to the hospital market, which it sells primarily throughout North America. It is focused on developing, manufacturing, sourcing and marketing injectable pharmaceutical products to the hospital market. It operates through two segments: Sagent US, consisting of the Company's operations in the United States and the Sagent (China) Pharmaceuticals Co. Ltd. (SCP) manufacturing facility, and Omega, which is focused on the Canadian and international markets. It offers a range of products across anti-infective, oncology and critical care indications in a range of presentations, including single and multi-dose vials, pre-filled ready-to-use syringes and premix bags. Its Sagent US product portfolio includes approximately 60 marketed products that it offers in over 180 presentations, and its Omega segment offers over 50 products.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: SGNT
  • CUSIP: 78669210
Key Metrics:
  • Previous Close: $21.76
  • 50 Day Moving Average: $21.72
  • 200 Day Moving Average: $15.37
  • 52-Week Range: $10.55 - $21.88
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 29.81
  • P/E Growth: 0.00
  • Market Cap: $N/A
  • Beta: 1.66
Additional Links:
Companies Related to Sagent Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Sagent Pharmaceuticals (NASDAQ:SGNT) (?)
Ratings Breakdown: 7 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $17.63 (19.00% downside)

Analysts' Ratings History for Sagent Pharmaceuticals (NASDAQ:SGNT)
DateFirmActionRatingPrice TargetDetails
8/11/2016Deutsche Bank AGDowngradeBuy -> HoldView Rating Details
7/12/2016Raymond James Financial Inc.DowngradeBuy -> Market PerformView Rating Details
7/11/2016Royal Bank Of CanadaDowngradeOutperform -> HoldView Rating Details
7/11/2016Piper Jaffray Cos.DowngradeOverweight -> Neutral$22.00 -> $21.75View Rating Details
6/17/2016Jefferies GroupReiterated RatingHold$13.00 -> $15.00View Rating Details
6/1/2016JPMorgan Chase & Co.Reiterated RatingNeutralView Rating Details
5/9/2016Bank of America Corp.Reiterated RatingHold$13.00View Rating Details
(Data available from 10/25/2014 forward)


Earnings History for Sagent Pharmaceuticals (NASDAQ:SGNT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2016Q1$0.01($0.15)$74.30 million$67.30 millionViewN/AView Earnings Details
2/16/2016Q415($0.02)($0.55)$78.13 million$83.10 millionViewListenView Earnings Details
11/3/2015Q315($0.07)$0.01$73.84 million$75.20 millionViewN/AView Earnings Details
8/4/2015Q215$0.05($0.01)$83.28 million$77.30 millionViewN/AView Earnings Details
5/5/2015Q115$0.04$0.04$80.63 million$82.60 millionViewN/AView Earnings Details
2/19/2015Q414$0.01$0.91$76.20 million$84.40 millionViewN/AView Earnings Details
11/4/2014Q314($0.04)$0.08$64.01 million$65.40 millionViewN/AView Earnings Details
7/30/2014Q214($0.01)$0.09$67.14 million$69.20 millionViewListenView Earnings Details
5/6/2014Q114($0.02)$0.16$65.66 million$70.90 millionViewListenView Earnings Details
2/11/2014Q4($0.01)$0.11$60.25 million$64.10 millionViewListenView Earnings Details
11/5/2013($0.03)$0.10ViewN/AView Earnings Details
8/6/2013Q2 2013$0.46$59.27 million$59.60 millionViewN/AView Earnings Details
5/6/2013Q1 2013($0.03)$0.34$55.31 million$60.20 millionViewN/AView Earnings Details
11/8/2012Q312($0.20)($0.13)$48.60 million$49.40 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Sagent Pharmaceuticals (NASDAQ:SGNT)
Current Year EPS Consensus Estimate: $0.24 EPS
Next Year EPS Consensus Estimate: $0.73 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.06$0.06$0.06
Q2 20161($0.19)($0.19)($0.19)
Q3 20161$0.19$0.19$0.19
Q4 20161$0.35$0.35$0.35
(Data provided by Zacks Investment Research)


Dividend History for Sagent Pharmaceuticals (NASDAQ:SGNT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Sagent Pharmaceuticals (NASDAQ:SGNT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/21/2016Ventures Fund V L.P. VivoMajor ShareholderSell2,005$13.55$27,167.75View SEC Filing  
11/4/2015Ventures Fund V L.P. VivoMajor ShareholderSell603,177$15.72$9,481,942.44View SEC Filing  
11/3/2015Vivo Ventures Vi, LlcMajor ShareholderSell67,283$16.32$1,098,058.56View SEC Filing  
11/2/2015Vivo Ventures Vi, LlcMajor ShareholderSell93,523$16.87$1,577,733.01View SEC Filing  
1/27/2015Morgan Stanley Investment ManaMajor ShareholderSell78,041$26.16$2,041,552.56View SEC Filing  
1/23/2015Morgan Stanley Investment ManaMajor ShareholderSell211,883$25.61$5,426,323.63View SEC Filing  
1/21/2015Morgan Stanley Investment ManaMajor ShareholderSell69,316$25.23$1,748,842.68View SEC Filing  
1/16/2015Morgan Stanley Investment ManaMajor ShareholderSell125,000$25.16$3,145,000.00View SEC Filing  
1/14/2015Morgan Stanley Investment ManaMajor ShareholderSell100,000$25.51$2,551,000.00View SEC Filing  
10/8/2014Robert J FlanaganDirectorSell16,000$31.56$504,960.00View SEC Filing  
10/7/2014Robert J FlanaganDirectorSell8,000$31.15$249,200.00View SEC Filing  
9/25/2014Robert J FlanaganDirectorSell16,000$30.01$480,160.00View SEC Filing  
9/24/2014Robert J FlanaganDirectorSell8,000$30.30$242,400.00View SEC Filing  
9/12/2014Robert J FlanaganDirectorSell16,000$28.30$452,800.00View SEC Filing  
9/11/2014Robert J FlanaganDirectorSell8,000$28.35$226,800.00View SEC Filing  
8/28/2014Robert J FlanaganDirectorSell16,000$27.19$435,040.00View SEC Filing  
8/27/2014Robert J FlanaganDirectorSell8,000$27.30$218,400.00View SEC Filing  
8/12/2014Robert J FlanaganDirectorSell16,000$24.39$390,240.00View SEC Filing  
7/31/2014Robert J FlanaganDirectorSell16,000$25.60$409,600.00View SEC Filing  
7/18/2014Robert J FlanaganDirectorSell16,000$26.18$418,880.00View SEC Filing  
7/2/2014Robert J FlanaganDirectorSell16,000$26.51$424,160.00View SEC Filing  
6/18/2014Robert J FlanaganDirectorSell16,000$23.37$373,920.00View SEC Filing  
6/4/2014Robert J FlanaganDirectorSell16,000$22.17$354,720.00View SEC Filing  
5/22/2014Robert FlanaganDirectorSell8,000$22.02$176,160.00View SEC Filing  
2/27/2014Michael LogerfoInsiderSell2,021$21.43$43,310.03View SEC Filing  
10/3/2013Morgan Stanley Investment Manamajor shareholderSell47,826$20.27$969,433.02View SEC Filing  
9/26/2013Morgan Stanley Investment Manamajor shareholderSell67,965$20.37$1,384,447.05View SEC Filing  
9/25/2013Morgan Stanley Investment Manamajor shareholderSell48,124$21.30$1,025,041.20View SEC Filing  
9/23/2013Morgan Stanley Investment Manamajor shareholderSell119,557$21.83$2,609,929.31View SEC Filing  
9/19/2013Morgan Stanley Investment Manamajor shareholderSell88,885$22.53$2,002,579.05View SEC Filing  
9/16/2013Frank KungDirectorSell1,161,717$21.25$24,686,486.25View SEC Filing  
9/16/2013Jeffrey YordonCEOSell85,813$20.03$1,718,834.39View SEC Filing  
9/16/2013Vivo Ventures Vi, Llcmajor shareholderSell622,700$21.25$13,232,375.00View SEC Filing  
8/12/2013Lorin DrakeVPSell1,000$23.69$23,690.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Sagent Pharmaceuticals (NASDAQ:SGNT)
News IconSagent Pharmaceuticals, Inc. (NASDAQ:SGNT) Latest Broker Coverage - NewsDen (NASDAQ:SGNT) - October 21 at 10:51 AM
News IconBroker Roundup For Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) - The De Soto Edge (NASDAQ:SGNT) - October 5 at 12:37 PM
News IconSEC Exclusive: * Verifone Hldgs INC (PAY) Shareholder Penn Capital Management Co INC Lowered Its Holding - Chester News (NASDAQ:SGNT) - October 4 at 6:51 PM
News IconLatest Analyst Ratings For Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) - The De Soto Edge (NASDAQ:SGNT) - September 30 at 2:48 PM
News IconSagent Pharmaceuticals' (SGNT) Overweight Rating Reiterated at Piper Jaffray - DailyQuint (NASDAQ:SGNT) - September 21 at 11:21 AM
News IconNWQ Bought 12 New Holdings in 2nd Quarter - Yahoo Sports (NASDAQ:SGNT) - September 16 at 7:00 PM logoNWQ Bought 12 New Holdings in 2nd Quarter (NASDAQ:SGNT) - September 16 at 7:00 PM
News IconPlacing Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) Shares Under the Microscope - Post News (NASDAQ:SGNT) - September 8 at 6:57 PM logoForm 4 Sagent Pharmaceuticals, For: Aug 29 Filed by: Krizman Anthony (NASDAQ:SGNT) - September 1 at 7:13 PM
News IconStock in Review: Taking a Closer Look at Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) Shares - Post News (NASDAQ:SGNT) - September 1 at 10:28 AM
News IconNichi-Iko Pharmaceutical Co., Ltd. Announces Results of Tender Offer to Purchase All of the ... (NASDAQ:SGNT) - August 30 at 10:37 AM logoNichi-Iko Pharmaceutical Co., Ltd. (NASDAQ:SGNT) - August 30 at 10:37 AM logoNichi-Iko Pharmaceutical Co., Ltd. Announces Results of Tender Offer to Purchase All of the Outstanding Shares of Common Stock of Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) - August 29 at 7:14 PM logoSAGENT PHARMACEUTICALS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delist (NASDAQ:SGNT) - August 29 at 7:14 PM logoCan Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) Surprise Analysts This Quarter? - Investor Newswire (NASDAQ:SGNT) - August 29 at 11:54 AM logoBRIEF-Nichi-Iko Pharmaceutical fully buys Sagent Pharmaceuticals, Inc. via takeover bid (NASDAQ:SGNT) - August 28 at 10:24 PM logoSagent Pharmaceuticals, Inc. (NASDAQ:SGNT) Gets 0 Recommendations To Sell - Investor Newswire (NASDAQ:SGNT) - August 26 at 10:18 AM
News IconIs it Time to Buy Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT)? The Consensus Is In - Post News (NASDAQ:SGNT) - August 25 at 12:28 PM
News IconInvestor News: Lawsuit against Buyout of Sagent Pharmaceuticals Inc (NASDAQ:SGNT) filed (NASDAQ:SGNT) - August 23 at 11:53 AM
News IconInvestor News: Lawsuit against Buyout of Sagent Pharmaceuticals Inc (NASDAQ:SGNT) filed - GroundReport (NASDAQ:SGNT) - August 22 at 7:17 PM
News IconRatings & Crowd Appeal on Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) - Post News (NASDAQ:SGNT) - August 20 at 11:22 AM logoWill Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) Hit $21.75 Price Target? - Investor Newswire (NASDAQ:SGNT) - August 19 at 7:17 PM logoAnalysts See Sales Of $503.34 For Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) - Investor Newswire (NASDAQ:SGNT) - August 19 at 7:17 PM
News IconActive Watchful Movers- NetApp, Inc. (NASDAQ:NTAP), AT&T, Inc. (NYSE:T), Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) (NASDAQ:SGNT) - August 18 at 10:27 AM logoSagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Oxacillin for Injection, USP, 10 g due to presence of iron oxide particulate matter (NASDAQ:SGNT) - August 17 at 7:45 PM logoSAGENT PHARMACEUTICALS, INC. Financials (NASDAQ:SGNT) - August 16 at 7:30 PM logoLawsuit for Investors in Sagent Pharmaceuticals Inc (NASDAQ:SGNT) Against Buyout Filed (NASDAQ:SGNT) - August 15 at 7:47 PM logoSagent Pharmaceuticals, Inc. (NASDAQ:SGNT) Records An Estimated Annual Sales Mean Of $503.34 - Investor Newswire (NASDAQ:SGNT) - August 12 at 7:29 PM logoETF’s with exposure to Sagent Pharmaceuticals, Inc. : August 12, 2016 (NASDAQ:SGNT) - August 12 at 7:29 PM logoSagent Pharmaceuticals, Inc. :SGNT-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 (NASDAQ:SGNT) - August 10 at 7:54 PM logoGainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Sagent Pharmaceuticals, Inc. (SGNT) (NASDAQ:SGNT) - August 10 at 7:54 PM logoForm SC TO-T/A Sagent Pharmaceuticals, Filed by: Shepard Vision, Inc. (NASDAQ:SGNT) - August 9 at 7:41 PM logoNichi-Iko Pharmaceutical Co., Ltd. Announces Expiration of HSR Waiting Period for Proposed Acquisition of Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) - August 9 at 10:37 AM logoSAGENT PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:SGNT) - August 5 at 7:38 PM logoShepard Vision, Inc., a Wholly-Owned Subsidiary of … (NASDAQ:SGNT) - August 1 at 7:07 PM logoShepard Vision, Inc., a Wholly-Owned Subsidiary of Nichi-Iko Pharmaceutical Co., Ltd, Commences All-Cash … (NASDAQ:SGNT) - August 1 at 1:01 PM logoBRIEF-Shepard Vision commences all-cash tender offer of $21.75 net per share to buy shares of Sagent (NASDAQ:SGNT) - August 1 at 11:43 AM
News IconInvestor News: Buyout of Sagent Pharmaceuticals Inc (NASDAQ:SGNT) faces Investigation (NASDAQ:SGNT) - July 29 at 10:28 AM logoCan Shares Of Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) Hit $21.75? - Investor Newswire (NASDAQ:SGNT) - July 28 at 7:41 PM logoSapiens Names Andre M. Boisvert Chairman of Sapiens DECISION Board of Directors (NASDAQ:SGNT) - July 28 at 9:28 AM logoIs $21.75 Price Target Attainable For Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT)? - Investor Newswire (NASDAQ:SGNT) - July 22 at 7:09 PM
News IconStock Observed in Overbought Territory: Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) - Press Telegraph (NASDAQ:SGNT) - July 22 at 7:09 PM
News IconSagent Pharmaceuticals Incorporated (NASDAQ:SGNT) Sellers Increased By 21.86% Their Shorts - Press Telegraph (NASDAQ:SGNT) - July 22 at 7:09 PM logoINVESTOR ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of Directors of Sagent Pharmaceuticals, Inc. Concerning the Sale of the Company to Nichi-Iko Pharmaceutical Co., Ltd. (NASDAQ:SGNT) - July 22 at 11:48 AM logoAcquisition of Sagent Pharmaceuticals Inc (NASDAQ:SGNT) Under Investigation for Investors (NASDAQ:SGNT) - July 21 at 7:44 PM logoSHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of Directors … (NASDAQ:SGNT) - July 20 at 8:18 PM logoSHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of Directors of Sagent Pharmaceuticals, Inc. Regarding the Sale of the Company to Nichi-Iko Pharmaceutical Co., Ltd. - SGNT (NASDAQ:SGNT) - July 20 at 4:16 PM
News IconSagent Pharmaceuticals, Inc. (NASDAQ:SGNT): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:SGNT) - July 20 at 10:17 AM logoSagent Pharmaceuticals (SGNT) Launches Amikacin Sulfate Injection, USP - (NASDAQ:SGNT) - July 20 at 10:17 AM logoAnalyst's Valuable Buzzers: Medtronic plc (NYSE:MDT) , Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) - Street Updates (NASDAQ:SGNT) - July 20 at 10:17 AM


Sagent Pharmaceuticals (NASDAQ:SGNT) Chart for Tuesday, October, 25, 2016

Last Updated on 10/25/2016 by Staff